期刊文献+

实验室自建项目在现代医学发展中面临的机遇和挑战 被引量:10

Laboratory developed tests in the development of modern medicine: opportunities and challenges
原文传递
导出
摘要 转化医学和个体化医学正在成为现代医学发展的新动力。技术为基础发展壮大起来的实验室自建项目(LDTs)是转化医学和个体化医学实施和发展过程中迫切需要和十分重要的一环。现代的LDTs多指采用细胞遗传学或分子生物学试验方法,分析核酸、线粒体、蛋白组和代谢组生物标志物、细胞表面分子等的体外诊断试验,常用于检测遗传性或获得性疾病相关的基因型、突变型或表型;病变细胞的分类等。目前对新一代LDTs的规范和监管正在探讨中。临床实验室应逐步建立完善LDTs的检测平台、质量控制体系和管理标准,搭建起科学研究与临床应用之间转化沟通的桥梁。 Translational medicine and personalized medicine are becoming the new power in modern medical development. Laboratory Developed Tests ( LDTs ) based on molecular biology and bioinformatics technology play a vital role in the development process of translational medicine and personalized medicine. Nowadays, LDTs consist of a broad range of in vitro diagnositc tests performed to analyze nucleic acid, chromosomes,proteins, certain metabolites and cell surface molecules using immunological technique, cytogenetic or molecular methods or a combination-of these methods. These LDTs are used to detect heritable or acquired disease-related genotypes, mutations, or phenotypes, and also used to classify the pathological changes of cells for clinical purposes. New generation LDTs, present some unique regulatory questions still remain to be discussed. Clinicians should capture the opportunity to establish and continuously improve the detection platforms of LDTs, the quality control system and management standards. On this basis, transformation bridges between scientific research and clinical application will be truly built.
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2015年第1期10-12,共3页 Chinese Journal of Laboratory Medicine
关键词 转化医学研究 个体化医学 临床实验室技术 分子诊断技术 Translational medical research Individualized medicine Clinical laboratory technique Molecular diagnostic techniques
  • 相关文献

参考文献11

  • 1Vandamme D,Fitzmaurice W, Kholodenko B, et al. Systemsmedicine : helping us understand the complexity of disease [ J ].QJM, 2013,106(10) :891-895.
  • 2Choi DW. Bench to bedside: the glutamate connection [ J ].Science, 1992,258(5080):241-243.
  • 3American Society for Clinical Pathology. Regulation of laboratorydeveloped tests( Policy Numberl0-02) ,2010.
  • 4Bill Malone. Regulation of Lab-developed tests [J/OL]. ClinicalLaboratory News, 2010,36 ( 9 ) : 4 [ 2010-09 ]. http://www.aacc. org/publications/ cln/2010/ september/Pages/ CoverStoryl.aspx.
  • 5Chen B, Gagnon M, Shahangian S, et al. Good laboratorypracitices for molecular genetic testing for heriable diseases andcondition[ J]. MMWR Recomm Rep,2009,58( RR-6) : 1 -37.
  • 6中华人民共和国卫生部.临床基因扩增检验实验室管理办法.2010-12-06.
  • 7Weiss RL. The long and winding regulatory road for laboratory-developed tests[ J] . Am J Clinical pathol, 2012,138(1):20-26.
  • 8吕时铭,朱宇宁.产前筛查与产前诊断的发展与思考[J].中华检验医学杂志,2014,37(4):241-244. 被引量:10
  • 9Federal Food, Drug and Cosmetic Act of 1994 ( FD&C) . 21 USC301-395(1994).
  • 10Scott MG, Ashwood ER, Annesley TM, et al. FDA Oversight ofLboratory-Developed Tests: Is It Necessary, and How Would ItImpact Clinical Lboratory. [ J ]. Chin Chem, 2013,59 ( 7 ):1017-1022.

二级参考文献61

  • 1Wright De.提高产前筛查质量:英国的经验[J].中国产前诊断杂志(电子版),2010(4):51-51. 被引量:2
  • 2刘艳荣,王卉,常艳,程翼飞,付家瑜,张乐萍,刘桂兰,陈珊珊.四色流式细胞术检测急性B淋巴细胞白血病残留细胞[J].中华血液学杂志,2005,26(6):327-331. 被引量:13
  • 3中华人民共和国卫生部.中国出生缺陷防治报告[R].北京:中华人民共和国卫生部,2012.
  • 4卫生部医疗服务标准专业委员会.WS322.1胎儿常见染色体异常与开放性神经管缺陷的产前筛查与诊断技术标准[S].北京:中国标准出版社,2010.
  • 5Palomaki GE, Deciu C, Kloza EM, et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome:an international collaborative study[ J]. Genet Med, 2012, 14:296-305.
  • 6Mann K, Ogilvie CM. QF-PCR:application, overview and review of the literature[J]. Prenat Diagn, 2012, 32:309-314.
  • 7Miller DT, Adam MP, Aradhya S, et al. Consensus statement:chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies[ J]. Am J Hum Genet, 2010, 86:749-764.
  • 8Wapner R J, Martin CL, Levy B, et al. Chromosome microarray versus Karyotyping for prenatal diagnosis [ J ]. N Engl J Med, 2012,367:2175- 2184.
  • 9Institute CaLS. Enumeration of Immunologieally Defined Cell Populations by Flow Cytometry; Approved Guideline[A].Wayne,PA:Clinical and Laboratory Standards Institute,2007.16.
  • 10Institute CaLS. Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells; Approved Guideline,2nd ed.CLSI document H43-A2[A].2007.16.

共引文献26

同被引文献90

  • 1中国实验室国家认可委员会技术委员会医学分委会.医学实验室质量管理与认可指南[M].北京:中国计量出版社,2004.
  • 2Scott MG, Ashwood ER, Annesley TM, et al. FDA oversight of laboratory-developed tests: is it necessary, and how would it impact clinical laboratories?[J]. Clin Chem, 2013, 59(7): 1017 - 1022.
  • 3中国合格评定国家认可委员会.医学实验室质量和能力认可准则在临床微生物学检验领域的应用说明(CNAS-CL42).北京:2012.
  • 4中华人民共和国卫生部.2013年全国抗菌药物临床应用专项整治活动方案.北京:2013.
  • 5Thomson RB, Gary VD. What will the role of the clinical microbiology laboratory director be in 2015[J]? J Clin Microbiol, 2011,49:S68-S71.
  • 6Bhattacharya S. Clinical microbiology: should microbiology be a clinical or a laboratory specialty[J]? Indian J Pathol Microbiol, 2010, 53(9): 217-221.
  • 7Crema M, Verbano C. Guidelines for overcoming hospital managerial challenges: a systematic literature review[J]. Ther Clin Risk Manag, 2013, 9:427-441.
  • 8Thomson RB Jr, Wilson ML, Weinstein ME The clinical microbiology laboratory director in the United States hospital setting[J]. J Clin Microbiol, 2010,48 (10):3465-3469.
  • 9Rosner, W, Auchus, R J, Azziz, R, et al. Position statement : Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement [ J ]. J Clin Endocrinol Metab, 2007, 92(2) : 405-413.
  • 10Rosner W. Another reference measurement procedure for total testosterone-what's the fuss? [ J]. Clin Chemy, 2013, 59 (2) : 338-339.

引证文献10

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部